Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth

Roberto Bianchi; Alessandra Gilardini; Virginia Rodriguez-Menendez; Norberto Oggioni; Annalisa Canta; Tina Colombo; Giulia De Michele; Sara Martone; Alessandra Sfacteria; Giuseppe Piedemonte; Giovanni Grasso; Patrizia Beccaglia; Pietro Ghezzi; Maurizio D'Incalci; Giuseppe Lauria; Guido Cavaletti

doi:10.1016/j.ejca.2006.09.028

Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth

Roberto Bianchi, Alessandra Gilardini, Virginia Rodriguez-Menendez, Norberto Oggioni, Annalisa Canta, Tina Colombo, Giulia De Michele, Sara Martone, Alessandra Sfacteria, Giuseppe Piedemonte, Giovanni Grasso, Patrizia Beccaglia, Pietro Ghezzi, Maurizio D'Incalci, Giuseppe Lauria, Guido Cavaletti

Research output: Contribution to journal › Article

Abstract

This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.

Original language	English
Pages (from-to)	710-717
Number of pages	8
Journal	European Journal of Cancer
Volume	43
Issue number	4
DOIs	https://doi.org/10.1016/j.ejca.2006.09.028
Publication status	Published - Mar 2007

Keywords

Cisplatin
Erythropoietin
Neurophysiology
Pathology
Peripheral neuropathy
Rat
Tumour growth

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.ejca.2006.09.028

Fingerprint Dive into the research topics of 'Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth'. Together they form a unique fingerprint.

Cite this

Bianchi, R., Gilardini, A., Rodriguez-Menendez, V., Oggioni, N., Canta, A., Colombo, T., Michele, G. D., Martone, S., Sfacteria, A., Piedemonte, G., Grasso, G., Beccaglia, P., Ghezzi, P., D'Incalci, M., Lauria, G., & Cavaletti, G. (2007). Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth. European Journal of Cancer, 43(4), 710-717. https://doi.org/10.1016/j.ejca.2006.09.028

Cisplatin-induced peripheral neuropathy : Neuroprotection by erythropoietin without affecting tumour growth. / Bianchi, Roberto; Gilardini, Alessandra; Rodriguez-Menendez, Virginia; Oggioni, Norberto; Canta, Annalisa; Colombo, Tina; Michele, Giulia De; Martone, Sara; Sfacteria, Alessandra; Piedemonte, Giuseppe; Grasso, Giovanni; Beccaglia, Patrizia; Ghezzi, Pietro; D'Incalci, Maurizio ; Lauria, Giuseppe; Cavaletti, Guido.

In: European Journal of Cancer, Vol. 43, No. 4, 03.2007, p. 710-717.

Research output: Contribution to journal › Article

Bianchi, R, Gilardini, A, Rodriguez-Menendez, V, Oggioni, N, Canta, A, Colombo, T, Michele, GD, Martone, S, Sfacteria, A, Piedemonte, G, Grasso, G, Beccaglia, P, Ghezzi, P, D'Incalci, M , Lauria, G & Cavaletti, G 2007, 'Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth', European Journal of Cancer, vol. 43, no. 4, pp. 710-717. https://doi.org/10.1016/j.ejca.2006.09.028

Bianchi, Roberto ; Gilardini, Alessandra ; Rodriguez-Menendez, Virginia ; Oggioni, Norberto ; Canta, Annalisa ; Colombo, Tina ; Michele, Giulia De ; Martone, Sara ; Sfacteria, Alessandra ; Piedemonte, Giuseppe ; Grasso, Giovanni ; Beccaglia, Patrizia ; Ghezzi, Pietro ; D'Incalci, Maurizio ; Lauria, Giuseppe ; Cavaletti, Guido. / Cisplatin-induced peripheral neuropathy : Neuroprotection by erythropoietin without affecting tumour growth. In: European Journal of Cancer. 2007 ; Vol. 43, No. 4. pp. 710-717.

@article{38f093b848ac4ffcb882a903cb926801,

title = "Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth",

abstract = "This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.",

keywords = "Cisplatin, Erythropoietin, Neurophysiology, Pathology, Peripheral neuropathy, Rat, Tumour growth",

author = "Roberto Bianchi and Alessandra Gilardini and Virginia Rodriguez-Menendez and Norberto Oggioni and Annalisa Canta and Tina Colombo and Michele, {Giulia De} and Sara Martone and Alessandra Sfacteria and Giuseppe Piedemonte and Giovanni Grasso and Patrizia Beccaglia and Pietro Ghezzi and Maurizio D'Incalci and Giuseppe Lauria and Guido Cavaletti",

year = "2007",

month = mar,

doi = "10.1016/j.ejca.2006.09.028",

language = "English",

volume = "43",

pages = "710--717",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Cisplatin-induced peripheral neuropathy

T2 - Neuroprotection by erythropoietin without affecting tumour growth

AU - Bianchi, Roberto

AU - Gilardini, Alessandra

AU - Rodriguez-Menendez, Virginia

AU - Oggioni, Norberto

AU - Canta, Annalisa

AU - Colombo, Tina

AU - Michele, Giulia De

AU - Martone, Sara

AU - Sfacteria, Alessandra

AU - Piedemonte, Giuseppe

AU - Grasso, Giovanni

AU - Beccaglia, Patrizia

AU - Ghezzi, Pietro

AU - D'Incalci, Maurizio

AU - Lauria, Giuseppe

AU - Cavaletti, Guido

PY - 2007/3

Y1 - 2007/3

N2 - This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.

AB - This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.

KW - Cisplatin

KW - Erythropoietin

KW - Neurophysiology

KW - Pathology

KW - Peripheral neuropathy

KW - Rat

KW - Tumour growth

UR - http://www.scopus.com/inward/record.url?scp=33947703740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947703740&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.09.028

DO - 10.1016/j.ejca.2006.09.028

M3 - Article

C2 - 17251006

AN - SCOPUS:33947703740

VL - 43

SP - 710

EP - 717

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -